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Serotonin 5-HT7 receptors are expressed in the hippocampus and modulate the
excitability of hippocampal neurons. We have previously shown that 5-HT7 receptors
modulate glutamate-mediated hippocampal synaptic transmission and long-term
synaptic plasticity. In particular, we have shown that activation of 5-HT7 receptors
reversed metabotropic glutamate receptor-mediated long-term depression (mGluR-LTD)
in wild-type (wt) and in Fmr1 KO mice, a mouse model of Fragile X Syndrome in which
mGluR-LTD is abnormally enhanced, suggesting that 5-HT7 receptor agonists might be
envisaged as a novel therapeutic strategy for Fragile X Syndrome. In this perspective, we
have characterized the basic in vitro pharmacokinetic properties of novel molecules with
high binding affinity and selectivity for 5-HT7 receptors and we have tested their effects
on synaptic plasticity using patch clamp on acute hippocampal slices. Here we show
that LP-211, a high affinity selective agonist of 5-HT7 receptors, reverses mGluR-LTD
in wt and Fmr1 KO mice, correcting a synaptic malfunction in the mouse model of
Fragile X Syndrome. Among novel putative agonists of 5-HT7 receptors, the compound
BA-10 displayed improved affinity and selectivity for 5-HT7 receptors and improved
in vitro pharmacokinetic properties with respect to LP-211. BA-10 significantly reversed
mGluR-LTD in the CA3-CA1 synapse in wt and Fmr1KO mice, indicating that BA-10
behaved as a highly effective agonist of 5-HT7 receptors and reduced exaggerated
mGluR-LTD in a mouse model of Fragile X Syndrome. On the other side, the compounds
RA-7 and PM-20, respectively arising from in vivo metabolism of LP-211 and BA-10,
had no effect on mGluR-LTD thus did not behave as agonists of 5-HT7 receptors
in our conditions. The present results provide information about the structure-activity
relationship of novel 5-HT7 receptor agonists and indicate that LP-211 and BA-10 might
be used as novel pharmacological tools for the therapy of Fragile X Syndrome.
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Introduction
Serotonin (5-HT) is a monoamine neurotransmitter control-
ling several physiological functions among which mood, circa-
dian rhythms, body temperature, food intake and nociception.
Seven main families (5-HT1 through 5-HT7) and at least 14
subtypes of 5-HT receptors have been identified to date (Han-
non and Hoyer, 2008; Nichols and Nichols, 2008). In the last
decade, an important role of 5-HT7 receptors in learning and
memory has emerged. Serotonin is released in the hippocampus
(one of the brain structures most crucially involved in learning)
by fibers arising from raphe nuclei (Segal, 1990; Schmitz et al.,
1998). 5-HT7 receptors are expressed in the hippocampus and
modulate neuronal excitability and synaptic transmission (Costa
et al., 2012b). Behavioral studies performed on wild-type animals
(Perez-Garcia and Meneses, 2005; Eriksson et al., 2008; Freret
et al., 2014; Meneses et al., 2015) and on mice lacking 5-HT7
receptors (5-HT7 KO) (Sarkisyan and Hedlund, 2009) indicate
that 5-HT7 receptor activation exerts a pro-cognitive action. In
light of this, 5-HT7 receptors have recently been proposed as a
novel target in cognitive diseases (Matthys et al., 2011; Ciranna
and Catania, 2014; Gasbarri and Pompili, 2014).
Fragile X Syndrome (FXS) is the most common form of inher-
ited intellectual disability, frequently associated with mood dis-
orders (Hagerman and Hagerman, 2002; Garber et al., 2008),
autism (Harris et al., 2008) and increased susceptibility to seizures
(Musumeci et al., 2001). FXS is caused by silencing of the Fmr1
gene coding for Fragile X Mental Retardation Protein (FMRP)
(Pieretti et al., 1991), an mRNA binding protein that func-
tions as a regulator of protein translation (Laggerbauer et al.,
2001; Bechara et al., 2009). One of the main consequences of
FMRP absence is a dysregulation of protein synthesis, leading
to altered synapse morphology and synaptic dysfunction (Bhakar
et al., 2012). The brain of FXS patients shows abnormal dendrite
morphology in cortex and hippocampus, with an overproduc-
tion of long, thin and immature dendritic spines (Irwin et al.,
2000). Evidence of synapse malfunction came from studies on
the Fmr1 gene knockout (Fmr1 KO) mouse, an animal model
of FXS that displays typical features resembling those of FXS
patients, among which alterations in dendritic spine morphol-
ogy (Comery et al., 1997; Nimchinsky et al., 2001) increased
susceptibility to audiogenic seizures (Musumeci et al., 2000)
and cognitive impairment (Bernardet and Crusio, 2006; Dolen
et al., 2007). In vitro studies on Fmr1 KO mice revealed that the
lack of FMRP dysregulates protein translation induced by acti-
vation of group I metabotropic glutamate receptors (mGluRs),
with an overproduction of proteins involved in AMPA recep-
tor endocytosis (Nakamoto et al., 2007). Consistently, mGluR-
mediated long-term depression (mGluR-LTD), a form of LTD
mediated by activation of mGlu5 receptors and leading to endo-
cytosis of AMPA receptors, is abnormally enhanced in the hip-
pocampus of Fmr1 KO mice (Huber et al., 2002). In line with
the “mGluR” theory of Fragile X Syndrome, pharmacological
blockade or reduced expression of group I mGlu receptors were
found to rescue cognitive impairment and abnormal behavior
in Fmr1 KO mice (Luscher and Huber, 2010; Bhakar et al.,
2012).
We have recently found that 5-HT7 receptor activation is
able to reverse mGluR-LTD and mGluR-mediated endocytosis of
AMPA receptors both in wild-type and in Fmr1 KO mice (Costa
et al., 2012a). These data suggest that abnormal mGluR-mediated
signaling in Fmr1 KO mice can be reversed by serotonin acting
through 5-HT7 receptors, suggesting that selective 5-HT7 recep-
tor agonists might become novel pharmacological tools for FXS
therapy.
In the present work, we have studied the effect of LP-
211, a selective and brain-penetrant agonist of 5-HT7 receptors
(Leopoldo et al., 2008; Hedlund et al., 2010) and of novel putative
agonists of 5-HT7 receptors in view of future preclinical studies
on Fmr1 KO mice.
Materials and Methods
Synthesis of 5-HT7 Receptor Ligands
The synthesis of the following 5-HT7 receptor ligands was
accomplished as previously reported:N-(4-cyanophenylmethyl)-
4-(2-diphenyl)-1-piperazinehexanamide, LP-211 (Leopoldo
et al., 2008), (R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-
yl]-3-(2-pyrazinyloxy)-2-propanol, BA-10 (Hansen et al., 2014),
N-(2-fluoropyridin-5-ylmethyl)-4-[2-(4-methoxy)phenyl]-1-pip
erazinehexanamide, PF-62 (Lacivita et al., 2014), 1-(2-
biphenyl)piperazine, RA-7 (Bantle, 1996), 1-[2-(4-meth-
oxyphenyl)phenyl]piperazine, PM-20 (Lacivita et al., 2012).
N -(4-cyanophenylmethyl)-3-[4-[2-(4-methoxyphenyl)phenyl]
pipe-razin-1-yl]ethoxy]propanamide, MM-1, and N-(4-trifuoro
methylphenylmethyl)-3-[4-[2-(4-methoxyphenyl)phenyl]pipe-
razin-1-yl]ethoxy]propanamide, MM-2, were synthesized as
depicted in Figure 1 (Scheme 1). RA-7 was alkylated with
2-bromoethanol to give alcohol 1 that underwent Michael
addition to t-butylacrylate to afford the ester 2. Acidic hydrolysis
of the ester afforded carboxylic acid 3 that was subsequently
condensed with 4-cyanophenylmethylamine or 4-trifuorometh-
ylphenylmethylamine to give the target compounds MM-1
and MM-2, respectively. These synthetic procedures involved
purification of intermediate and target compounds by column
chromatography on silica gel column. The chemical structure
of intermediate and target compounds was confirmed by NMR
spectroscopy, mass spectrometry and elemental analysis.
Evaluation of Metabolic Stability of Novel
High-Affinity 5-HT7 Ligands
In vitro metabolism of compounds BA-10, PF-62, MM-2, and
MM-1 was evaluated after incubation with mouse hepatic micro-
somes in the presence of an NADPH-generating system, accord-
ing to Jia and Liu (Jia and Liu, 2007). Test compounds were
pre-incubated at 37◦C with mouse liver microsomes (0.5 mg/mL
microsomal protein) at 1µM final concentration in 100mM
potassium phosphate buffer (pH 7.4) for 10min. Metabolic reac-
tions were initiated by the addition of a NADPH regenerating
system (NADP, glucose-6-phosphate, glucose-6-phosphate dehy-
drogenase, final glucose-6-phosphate dehydrogenase concentra-
tion, 1 unit/mL). Aliquots were removed (0, 5, 10, 30, and 60min)
and immediately mixed with an equal volume of cold acetonitrile
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FIGURE 1 | Synthesis of Compounds MM-1 and MM-2. Reagents and
Conditions: (A) 2-bromoethanol, K2CO3, KI, acetonitrile, reflux overnight,
82% yield; (B) NaH, t-butyl acrylate, anhydrous THF, 0◦C to r.t., 20–22 h,
43% yield; (C) 3N HCl, dioxane, r.t., 48 h, quantitative yield; (D)
4-cyanophenylmethylamine or 4-trifuoromethylphenylmethylamine,
1,1’-carbonyldimidazole, anhydrous THF, r.t., overnight, 95% yield.
containing internal standard. Test compound incubated with
microsomes without NADPH regenerating system for 60minwas
included. Quenched samples were centrifugated at 4500 rpm for
15min and the supernatants were analyzed by reversed phase
HPLC. Quantitation of the parent compound at the various time
points was performed using Agilent 1290 Infinity LC System
equipped with diode array detector. The column used was a
Phenomenex Gemini C-18 (250 × 4.6mm, 5µm particle size).
The samples were isocratically eluted using CH3CN/ammonium
formate (20mM, pH 5.5) 7:3 (v/v) as mobile phase. The chro-
matograms were registered at three different wavelenghts (230,
254, and 280 nm).
Natural logarithm of percentage remaining vs. time data for
each compound was fitted to linear regression and the slope was
used to calculate the degradation half-life (t1/2) according to the
equation (Obach et al., 1997):
t1/2 :
0.693
k
In vitro half-life was then used to calculate the intrinsic plasma
clearance (CLint) according to the following equation (Obach
et al., 1997):
CLint
0.693
t1/2
•
volume of incubation (µL)
protein in the incubation
Electrophysiology
Patch clamp experiments were performed on mouse
hippocampal slices from wild-type (wt) mice (FVB and
C57BL/6J background) and Fmr1 KO2 mice (C57BL/6J back-
ground, kindly provided by Prof. Willemsen, Erasmus MC,
Rotterdam, The Netherlands). Animal care and experimental
procedures were performed in accordance with the European
Communities Council guidelines 86/609/EEC. Every care was
taken to maximally reduce the number of animals and to
minimize discomfort.
Acute hippocampal slices from wt and Fmr1 KO mice (age
14–21 days) were prepared as previously described (Costa et al.,
2012a,b). Briefly, the brain was rapidly removed and placed
in oxygenated ice-cold artificial cerebro-spinal fluid (ACSF; in
mM NaCl 124; KCl 3.0; NaH2PO4 1.2; MgSO4 1.2; CaCl2 2.0;
NaHCO3 26; D-glucose 10, pH 7.3). Acute hippocampal slices
(300µM) were cut with a vibratome (Leica VT 1200). Slices
were continually perfused with oxygenated ACSF. After 3 h of
recovery, one slice was placed in the recording chamber of a
patch camp set up and viewed with infrared microscopy (Leica
DMLFS). A tungsten electrode was placed in the stratum radia-
tum to stimulate Schaffer collaterals with negative current pulses
(duration 0.3ms, delivered every 15 s by A310 Accupulser, WPI,
USA). Evoked AMPA receptor-mediated excitatory post-synaptic
currents (EPSCs) were recorded from CA1 pyramidal neurons
under whole-cell patch clamp (holding potential -70mV; EPC7-
plus amplifier HEKA, Germany). Stimulation intensity was set
to induce half-maximal EPSC amplitude. Series resistance (Rs)
was monitored throughout the recording by means of 10mV
hyperpolarizing pulses; recordings were discarded from anal-
ysis if Rs changed by more than 20%. EPSC traces were fil-
tered at 3 kHz and digitized at 10 kHz. Data were acquired and
analyzed using Signal software (CED, England). The record-
ing micropipette (resistance 1.5–3 M) was filled with intracel-
lular solution (in mM: K-gluconate 140; HEPES 10; NaCl 10;
MgCl2 2; EGTA 0.2; Mg-ATP 3.5; Na-GTP 1; pH 7.3). Bath
solution (ACSF; flow rate of 1.5ml/min) routinely contained
(-)-bicuculline methiodide (5µM, SIGMA) and D-(-)-2-Amino-
5-phosphonopentanoic acid (D-AP5, 50µM, Tocris). mGluR-
LTD of synaptic currents was chemically induced by application
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of the group I mGluR agonist DHPG (100µM, 5min) in the
absence and in the presence of a 5-HT7 receptor ligand. Phar-
macological agents (S-3,5-DHPG 100µM; LP-211 10 nM; BA-10
10 nM; RA-7 10 nM; PM-20 10 nM) were dissolved in ACSF and
applied by bath perfusion.
For LTD data analysis, peak amplitude values of evoked EPSCs
were averaged over 1min and expressed as % of control (cal-
culated from EPSCs recorded during at least 15min before
DHPG application). The amount of mGluR-LTD was calculated
45–55min after LTD induction by DHPG application and is
expressed by indicating EPSC amplitude as percentage of baseline
EPSC (% EPSC). Cumulative histograms indicate % EPSC ampli-
tude (mean ± SEM from groups of neurons) after application of
DHPG alone (control LTD) or DHPG followed by a 5-HT7 recep-
tor agonist. EPSC amplitude values from two groups of neurons
were compared using the Student’s t-test, with n indicating the
number of neurons tested in each condition.
Results
The 5-HT7 Receptor Agonist LP-211 reversed
mGluR-LTD in Wild-Type and Fmr1 KO Mice
Excitatory post-synaptic currents (EPSCs)mediated by glutamate
AMPA receptors were recorded from CA1 pyramidal neurons
following stimulation of Schaffer collaterals in hippocampal slices
fromwt and Fmr1 KOmice (C57BL6J background; post natal day
PN 14–21).
In slices from wt mice, bath application of DHPG (100µM,
5min), an agonist of group I metabotropic glutamate recep-
tors, induced a long term depression (mGluR-LTD) of synap-
tic currents (Figure 2A): EPSC amplitude measured 45min after
DHPG application (74.4 ± 9.8, mean ± SEM, n = 9) was signif-
icantly lower than control EPSC amplitude (99.97 ± 3.2, n = 9;
P < 0.01; Figure 2B).
In another group of recordings, LP-211 (10 nM, 5min)
was applied 5min after DHPG (Figure 2A): in these condi-
tions, EPSC amplitude measured 45min after DHPG applica-
tion (99.4 ± 1.5% of control, mean ± SEM, n = 5) was not
significantly different from control EPSC amplitude (P = 0.7,
Figure 2B), indicating that mGluR-LTD was completely reversed
by LP-211. This result fully confirms our previous data obtained
using the FVB mouse strain, showing that LP-211 reversed
mGluR-LTD in hippocampal slices from wild-type mice (Costa
et al., 2012a).
In slices from Fmr1 KO mice (C57BL6J background), appli-
cation of DHPG strongly reduced EPSC amplitude (EPSC mea-
sured 45min after DHPG: 56 ± 5% of control, mean ± SEM,
n = 7; Figure 2C), with a highly significant reduction with
respect to control EPSC (P < 0.00001, Figure 2D). The amount
of DHPG-induced inhibition in slices from Fmr1 KO mice was
significantly larger than in wt slices (EPSC amplitude: 74 ± 4%
of control, mean ± SEM, n = 9; P = 0.0069; compare black
columns in Figures 2B,D). This result confirms that mGluR-LTD
in Fmr1 KO mice was enhanced with respect to wt, in agreement
with previous data (Huber et al., 2002; Zhang et al., 2009; Choi
et al., 2011; Costa et al., 2012a).
Application of LP-211 after DHPG reversed mGluR-LTD also
in slices from Fmr1 KO mice (Figure 2C). Compared to wt,
reversal of mGluR-LTD by LP-211 in Fmr1 KO slices had a
slower time course: 45min after DHPG application, the amount
of mGluR-LTD was still significant (EPSC amplitude 78 ± 5%
of control, mean ± SEM, n = 6, P = 0.001, Figure 2D, upper
panel), but was significantly lower (P < 0.01) than that induced
by DHPG only. A full reversal of mGluR-LTD by LP-211 was
observed 55min after DHPG application: EPSC amplitude (97±
3% of control, mean ± SEM, n = 6) was not significantly
different from control EPSC (P = 0.07; Figure 2D, lower panel).
In Vitro Pharmacokinetic Properties of New
Putative 5-HT7 Receptor Agonists
The four new putative 5-HT7 receptor agonists BA-10, PF-62,
MM-2, and MM-1 were identified in our laboratory following a
medicinal chemistry campaign to obtain 5-HT7 receptor ligands
with the same structural scaffold of LP-211 but endowed with
improved metabolic stability (Table 1). These molecules incor-
porated chemical features known to improve metabolic stability,
such as electron withdrawing groups, or polar groups that reduce
the lipophilicity of the molecule, since it is known that high
lipophilicity is correlated with metabolic liability (Mannhold,
2006). The new compounds were initially tested for their bind-
ing affinity for 5-HT7 receptors. With respect to LP-211, BA-10,
and PF-62 displayed an increased affinity for 5-HT7 receptors,
whereas MM-1 and MM-2 respectively showed comparable and
lower affinity (Table 1). This indicated the correct design of the
new molecule that was aimed to obtain compounds with the
same profile as LP-211. Interestingly, all the compounds tested
showed improved selectivity for 5-HT7 over 5-HT1A receptors
with respect to LP-211 (Table 1).
In vitrometabolism of compounds BA-10, PF-62, MM-2, and
MM-1 was evaluated after incubation with mouse hepatic micro-
somes in the presence of an NADPH-generating system, accord-
ing to Jia and Liu (2007). Liver microsomes provide the most
convenient way to study cytochrome P450 enzyme-mediated
metabolism. Half-life (t1/2) and Intrinsic Clearance (CLInt) of the
test compounds are listed in Table 1. Half-life and intrinsic clear-
ance of MM-2 and MM-1 indicated that these compounds are
less metabolically stable than PF-62, LP-211 and BA-10. Instead,
BA-10 appeared endowed with higher metabolic stability than
LP-211. In particular, BA-10 displayed the longest in vitro half-
life among the five compounds examined, indicating improved
metabolic stability with respect to LP-211.
We next evaluated the eﬄux ratio (BA/AB) of PF-62, MM-2,
andMM-1 between basal-to-apical (BA) and apical-to-basal (AB)
fluxes in Caco-2 cells monolayer. This system is an in vitromodel
to evaluate the interaction of small molecules with P-glycoprotein
(P-gp), an eﬄux pump localized on the blood-brain barrier that
prevents xenobiotics to enter the brain. Therefore, a centrally act-
ing drug should not be a P-gp substrate. In this system, a cutoff
value of 3 is generally used to distinguish P-gp substrate from
nonsubstrate (Hitchcock, 2012). BA/AB ratios of the test com-
pounds are listed in Table 1: all the compounds tested appeared
to be weak substrates, thus should only weakly interact with P-gp.
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FIGURE 2 | LP-211 reversed mGluR-LTD in the hippocampus of
wild-type and Fmr1 KO mice. Excitatory post-synaptic currents (EPSCs)
mediated by AMPA receptors were recorded under whole-cell patch clamp
from CA1 pyramidal neurons after stimulation of Schaffer collaterals in the
continuous presence of the NMDA receptor antagonist D-AP5 (50µM).
EPSC amplitude is represented as percent of control EPSC amplitude prior
to any substance application. Pooled data of % EPSC values (mean ± SEM)
were plotted vs. time; insets show individual EPSC traces from representative
experiments. (A) Hippocampal slices (300µm) were prepared from wild-type
mice on a C57BL/6J background (PN 14-21). Bath application of DHPG
(100µM, 5min), an agonist of group I metabotropic glutamate receptors,
induced a long term depression of EPSC amplitude. In another group of
recordings, LP-211 (10 nM, 5min) was applied 5min after LTD induction.
Following application of LP-211, EPSC amplitude returned to control values
(100%), indicating that mGluR-LTD was reversed. (B) Histograms show
mean EPSC amplitude values (% of control) in control conditions (empty
column, n = 9) and 45min after application of DHPG alone (black column,
n = 9) or application of DHPG followed by LP-211 (dark gray column, n = 5).
Application of DHPG significantly reduced EPSC amplitude (∗P < 0.01), thus
induced mGluR-LTD. Vice-versa, when DHPG application was followed by
LP-211, EPSC values were not reduced with respect to control, indicating
that mGluR-LTD was completely reversed. (C) Hippocampal slices were
prepared from Fmr1 KO mice (C57BL6J strain; PN 14-21) Application of
DHPG (100µM, 5min) induced a long-term depression (mGluR-LTD) of
EPSC amplitude. When LP-211 (10 nM, 5min) was applied after DHPG,
mGluR-LTD was partially reversed. A complete reversal of mGluR-LTD was
observed around 55min after LTD induction. (D), upper panel: EPSC current
amplitude in control conditions (100%) and 45min after application of DHPG.
In slices from Fmr1 KO mice, the amount of mGluR-LTD induced by DHPG
alone was highly significant (black column; ∗∗∗∗P < 0.00001) and was larger
than in wild-type (compare with panel B). When DHPG application was
followed by application of LP-211, the amount of mGluR-LTD was still
significant (∗∗P < 0.001) but was significantly reduced (∗P < 0.01) with
respect to mGluR-LTD induced by DHPG alone, indicating that mGluR-LTD
was partially reversed. (D) Lower panel: EPSC current amplitude in control
conditions (100%) and 55min after application of DHPG: mGluR-LTD was
completely reversed by LP-211, indicating a slower time course of
LP-211-mediated reversal in Fmr1 KO with respect to wild-type.
In line with this, a recent positron emission tomography study
performed with [11C]BA-10 clearly showed in vivo that BA-10
is not a P-gp substrate, being able to massively accumulate into
the brain (Hansen et al., 2014), thus is likely to act on the central
nervous system following systemic administration.
In summary, among the new putative 5-HT7 receptor agonists
examined in the present study, the compound BA-10 displayed
improved affinity and selectivity for 5-HT7 receptors, together
with improved in vitro metabolic stability with respect to the
5-HT7 receptor agonist LP-211.
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TABLE 1 | Binding Affinity Data and Pharmacokinetic Parameters of Test Compounds.
Compound 5-HT7 Ki [nM] 5-HT1A Ki [nM] t1/2 (min) CLint (µL/mg/min) BA/AB
LP-211 15 188 10.6 131 4.0
BA-10 1.1 242 14.8 96 5.6
MM-1 16 437 2.7 515 3.3
MM-2 35 582 2.8 498 3.5
PF-62 3.82 152 6.7 205 4.2
The Novel Compound BA-10 Behaved as an
Agonist of 5-HT7 Receptors and Reversed
mGluR-LTD in the Hippocampus of Wild-Type
and Fmr1 KO Mice
We next tested the biological effect of BA-10 on native 5-HT7
receptors in the hippocampus of wild-type mice (PN 14–21).
When BA-10 (10 nM, 5min) was applied after DHPG, EPSC
amplitude returned to values comparable to control (EPSC
amplitude 45min after DHPG application: 107± 23% of control,
mean± SEM, n = 6; Figures 3A,B), indicating that mGluR-LTD
was reversed.
In slices from Fmr1KOmice (PN 14–20), application of BA-10
completely reversed DHPG-induced mGluR-LTD (Figure 3C):
DHPG induced a significant LTD when applied alone (P = 0.01,
Figure 3D) but not when applied together with BA-10 (P =
0.29, Figure 3D). The amount of mGluR-LTD after application
of DHPG alone or DHPG with BA-10 was significantly differ-
ent (EPSC amplitude respectively 56 ± 12% and 116 ± 11% of
control; P = 0.0054; Figure 3D).
These results indicate that BA-10, a novel compound with
improved pharmacokinetic properties with respect to known 5-
HT7 receptor agonists, is able to reverse mGluR-LTD in wild-type
mice and to rescue synaptic plasticity in Fmr1 KO mice, thus
might be envisaged as a new pharmacological tool for Fragile X
Syndrome.
The Compounds RA-7 and PM-20 did not Modify
mGluR-LTD
Pharmacokinetic studies have shown that LP-211 and BA-10 are
metabolized by liver enzymes, respectively giving rise to the com-
pouds RA-7 (Leopoldo et al., 2008) and PM-20 (Prof. Leopoldo,
unpublished results). A previous study showed that RA-7 and
PM-20 bind 5-HT7 receptors with higher affinity than LP-211
(Lacivita et al., 2012). Similar to LP-211, RA-7 is brain pene-
trant and induced hypothermia in wild-type but not in 5-HT7
KOmice following in vivo administration (Hedlund et al., 2010).
These results suggest that RA-7 might be able to activate 5-
HT7 receptors. Therefore, we tested the effects of RA-7 on
mGluR-LTD. In our experimental protocol, application of RA-7
(10 nM, 5min) after DHPG application did not reverse mGluR-
LTD (Figure 4A): EPSC amplitude measured 45min after DHPG
application was significantly reduced with respect to control
(64 ± 7% of control EPSC; mean ± SEM, n = 5; P<0.01).
The amount of mGluR-LTD following RA-7 application was not
significantly different from mGluR-LTD in control conditions
(P = 0.5, Figure 4C).
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FIGURE 3 | The novel 5-HT7 receptor ligand BA-10 reversed
mGluR-LTD in the hippocampus of wild-type and Fmr1 KO mice
Pooled data of % EPSC values (mean ± SEM) were plotted vs. time; insets
show individual EPSC traces from representative experiments. mGluR-LTD
was chemically induced by bath application of DHPG (100µM, 5min). (A,B)
In hippocampal slices (300µm) from wild-type mice (FVB; PN 14-21),
application of DHPG induced a significant mGluR-LTD (∗∗P = 0.007, n = 5).
When LTD induction was followed by application of BA-10 (10 nM, 5min),
EPSC amplitude was not significantly different from control (P = 0.75, n = 6),
indicating that mGluR-LTD was completely reversed. This result shows that
BA-10 behaved as an agonist of 5-HT7 receptors. (C,D) In slices from Fmr1
KO mice (C57BL6J, PN 14-20), application of DHPG (100µM, 5min)
induced a significant mGluR-LTD (∗P = 0.010, n = 6) that was completely
reversed when BA-10 (10 nM, 5min) was applied after DHPG (P = 0.29,
n = 6). The amount of LTD induced by DHPG in the absence and in the
presence of BA-10 was significantly different (∗∗P = 0.0054). This result
shows that BA-10 was able to reverse mGluR-LTD in a mouse model of
Fragile X Syndrome.
In a similar way, application of PM-20 did not reverse
DHPG-induced mGluR-LTD (Figure 4B): EPSC amplitude mea-
sured 45min after DHPG applicationwas significantly lower than
control (Figure 4C, EPSC amplitude 60± 7% of control, mean±
SEM, n = 5; P = 0.001). The amount of mGluR-LTD induced
by DHPG followed by PM-20 was not significantly different from
mGluR-LTD induced by application of DHPG alone (P = 0.9,
Figure 4C)
These results indicate that RA-7 and PM-20 were unable to
induce the same effect of their parent compounds LP-211 and
BA-10, thus did not behave as agonists of 5-HT7 receptors in our
experimental conditions.
Discussion
In a previous work, we have shown that 5-HT, through activation
of 5-HT7 receptors, is able to reverse exaggerated mGluR-LTD
in the Fmr1 KO mouse model of Fragile X Syndrome (FXS)
(Costa et al., 2012a). Exaggerated mGluR-LTD in Fmr1 KO mice
is considered an electrophysiological readout of abnormal signal-
ing through mGlu receptors (Bhakar et al., 2012). Our current
hypothesis is that activation of 5-HT7 receptors, by correct-
ing mGluR-mediated mechanisms in Fmr1 KO mice, besides
reversing abnormal mGluR-LTD can also rescue other typical
phenotypes of FXS, particularly abnormal dendrite morphol-
ogy, cognitive impairment and autistic behavior (Osterweil et al.,
2012; Ciranna and Catania, 2014). Interestingly, 5-HT7 recep-
tor activation was shown to stimulate neurite and dendrite out-
growth in cultured neurons and is believed to play a crucial role in
brain wiring during development (Volpicelli et al., 2014). These
data suggest that activation of 5-HT7 receptors might also correct
abnormal dendrite morphology in Fmr1 KO mice.
To test this hypothesis, selective and high-affinity 5-HT7
receptor agonists are needed: most importantly, the new agonists
must also display drug-like properties and reach the brain
following in vivo systemic administration. On this purpose,
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FIGURE 4 | RA-7 and PM-20 did not reverse mGluR-LTD in the
hippocampus of wild-type mice. Hippocampal slices (300µm) were
prepared from wild-type mice (FVB; PN 14-21). Pooled data of %
EPSC values (mean ± SEM) were plotted vs time; insets show
individual EPSC traces from representative experiments. When DHPG
application was followed by application of RA-7 (A; 10 nM, 5min) or
PM-20 (B; 10 nM, 5min), mGluR-LTD was not reversed. (C) Histograms
show mean EPSC amplitude (% of control) 45min after DHPG
application (empty column, n = 5); when DHPG application was
followed by application of either LP-211 (black column, n = 6) or
BA-10 (dark gray column, n = 5), EPSC amplitude was significantly
higher than following application of DHPG alone (∗∗P < 0.001;
∗P < 0.01 vs. DHPG alone, Student’s t-test), indicating that mGluR-LTD
was reversed. Vice-versa, RA-7 and PM-20 were unable to reverse
mGluR-LTD (no significant difference vs. DHPG alone), thus did not
behave as agonists of 5-HT7 receptors.
in the present work we have tested the effects of a brain-
permeant 5-HT7 receptor agonist (LP-211) and characterized the
pharmacokinetic properties and biological effects of a novel puta-
tive 5-HT7 receptor agonist (BA-10). We show that both sub-
stances are able to correct a synaptic malfunction in Fmr1 KO
mice, thus can be used for in vivo administration to Fmr1 KO
mice in preclinical behavioral studies.
LP-211 was designed and synthesized by the research group of
Prof. Leopoldo (compound 25 in (Leopoldo et al., 2008) and char-
acterized as a high-affinity, selective and brain-permeant 5-HT7
receptor agonist (Hedlund et al., 2010). In vivo administration of
LP-211 was shown to exert pro-cognitive effects in rats submitted
to an autoshaping learning task (Meneses et al., 2015).
Our previous results (Costa et al., 2012a) demonstrated that
LP-211 is able to reverse mGluR-LTD in wild-type mice. Here
we show that LP-211 reverses mGluR-LTD also in Fmr1KO
mice, in which mGluR-LTD is abnormally enhanced, suggesting
a potential therapeutic use of LP-211 in Fragile X Syndrome.
In slices from Fmr1KO mice, reversal of mGluR-LTD by LP-
211 showed a slower time-course with respect to wt. In addi-
tion we observed that, unlike in wt, in Fmr1 KO mice LP-211
did not fully reverse mGluR-LTD but rather restored LTD level
comparable to wt condition. This result is in agreement with
our previous observation that in Fmr1 KO mice 8-OH-DPAT
partially reduced the amount of mGluR-LTD and did not com-
pletely abolish it (Costa et al., 2012a). This might have impor-
tant functional consequences, since long-term synaptic plasticity
plays a fundamental role in shaping the structure and function of
brain circuits. A large body of evidence demonstrates that LTD
is crucially involved in learning and memory and pharmacologi-
cal or genetic manipulations disrupting LTD also impair learning
(Collingridge et al., 2010). Consistently, abnormal mGluR-LTD
has been observed in animal models of several cognitive dis-
eases including Fragile X Syndrome (D’Antoni et al., 2014). Inter-
estingly, LTD plays a crucial role in novelty detection and in
the extinction of previously acquired memories and is believed
to underlie behavioral flexibility (Collingridge et al., 2010). A
reduced behavioral flexibility, i.e., a reduced ability to face a new
environmental context, is a typical feature of autism spectrum
disorders. Fragile X Syndrome is a leading genetic cause of autism
(Hagerman et al., 2005) and alterations in behavioral flexibility
have been described in FXS patients (Hooper et al., 2008) as well
as in Fmr1KO mice (Bernardet and Crusio, 2006; Casten et al.,
2011; Krueger et al., 2011). We suggest that selective activation
of 5-HT7 receptors, by restoring mGluR-mediated synaptic plas-
ticity to normal levels, might also rescue cognitive functions and
behavioral flexibility in the mouse model of Fragile X Syndrome
(Ciranna and Catania, 2014). We will test this hypothesis in
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the near future by behavioral studies on wt and Fmr1 KO mice
following in vivo administration of a 5-HT7 receptor agonist.
As already pointed out, LP-211 is suitable as a centrally-active
substance following systemic administration, being able to pass
the blood brain barrier (Hedlund et al., 2010), but showed a rel-
atively short in vivo half-life (65min) when administered to mice
by intraperitoneal injection (Leopoldo et al., 2008). In the attempt
to identify a 5-HT7 receptor agonist with improved pharmacoki-
netic properties, we have designed and characterized a series of
new molecules structurally related to LP-211.
Among the novel compounds examined in the present work,
BA-10 displayed the most suitable pharmacokinetic properties
for systemic administration. Vice-versa, the compounds MM-1
and MM-2 displayed lower in vitrometabolic stability compared
to LP-211 and were not further considered for our study. As for
compound PF-62, in vitro pharmacokinetic properties did not
show any improvement with respect to LP-211. On the other
side, BA-10 displayed higher selectivity on 5-HT7 receptors and
improved metabolic stability with respect to LP-211. We show
that BA-10 significantly reversed mGluR-LTD (an effect medi-
ated by 5-HT through activation of 5-HT7 receptors, as we have
previously characterized) in the hippocampus of wild-type and
Fmr1 KO mice. These results demonstrate that BA-10 behaves
as an agonist of 5-HT7 receptors and is able to correct exagger-
ated mGluR-LTD in the mouse model of Fragile X Syndrome.
In slices from Fmr1 KO mice, reversal of mGluR-LTD by BA-
10 at a 10 nM dose was more significant than the effect induced
by LP-211 at the same concentration (compare Figures 2C,D and
Figures 3C,D). The higher effectiveness of BA-10 with respect to
LP-211 is in agreement with a 10 fold higher affinity of BA-10 vs.
LP-211 for 5-HT7 receptors, as wemeasured by radioligand bind-
ing assays (see Table 1), and indicates that BA-10 can be used at
very low (sub-nanomolar) doses to activate 5-HT7 receptors.
We observed that BA-10 showed a weak in vitro affinity for
interaction with P-glycoprotein, suggesting that BA-10 might
persist in CNS without being extruded by the blood brain bar-
rier when administered systemically. Consistently, in vivo results
recently published (Hansen et al., 2014) show that BA-10 is
not significantly transported by P-glycoprotein and reaches high
brain concentrations following intravenous injection. Therefore,
the pharmacokinetic properties of BA-10 are promising and
deserve to be further investigated.
RA-7 and PM-20, metabolites of LP-211 and BA-10 respec-
tively, were unable to reverse mGluR-LTD, thus did not behave
as agonists of 5-HT7 receptors in our experimental protocol. This
indicates that, following in vivo administration of LP-211 and BA-
10, their metabolites RA-7 and PM-20 do not exert a cooperative
action with parent compounds, as was hypothesized for RA-7
(Hedlund et al., 2010). The lack of agonist effect of RA-7 and PM-
20 also suggests that, following in vivo administration, the effects
of LP-211 and BA-10 are likely to be reduced with time as their
concentration is decreased by hepatic metabolism. Nevertheless,
several results indicate that LP-211 exerts long-term effects on
the brain. The first pharmacokinetic study on LP-211 (Leopoldo
et al., 2008) shows that the brain concentration of LP-211 in mice
remained high during at least 2 h after intraperitoneal injection.
The authors suggested that LP-211 is likely to be accumulated in
the brain, due to its high lipophilic properties. Besides, it should
be noticed that 2 h after injection, LP-211 brain concentration
declined below detectable levels, but might still be high enough
to activate 5-HT7 receptors, especially considering that LP-211
binds 5-HT7 receptors with very high affinity, with reported Ki
values between 0.58 nM (Leopoldo et al., 2008) and 15 nM (Hed-
lund et al., 2010). In line with this, we observed a reversal of
mGluR-LTD by a low nanomolar dose of LP-211 (10 nM). Con-
sistently, LP-211 has been administered in vivo in several studies
and was shown to exert long-term effects on functions regulated
by the central nervous system such as regulation of body temper-
ature, sleep and circadian rhythms (Hedlund et al., 2010; Adriani
et al., 2012; Monti et al., 2014). These results suggest that central
effects of LP-211 can be long-lasting in spite of a relatively short
half-life.
In conclusion, we show that the 5-HT7 receptor agonists
LP-211 and BA-10 correct a synaptic malfunction in Fmr1KO
mice, thus might become new pharmacological tools for the
therapy of Fragile X Syndrome. We also show that the novel
compound BA-10 is a highly effective 5-HT7 receptor agonist
with improved selectivity and in vitro pharmacokinetic proper-
ties with respect to LP-211, thus should also be considered for
in vivo studies.
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